India Inherited Disease Therapy Market Size & Growth Rate
According to 6Wresearch internal database and industry insights, the India Inherited Disease Therapy Market was valued at USD 611.0 million in 2025 and is projected to reach USD 854.02 million by 2032, growing at a CAGR of approximately 4.9% during 2026–2032.
India Inherited Disease Therapy Market Highlights
| Report Metric | Details |
| Report Name | India Inherited Disease Therapy Market |
| Market Size 2025 | USD 611.0 million |
| Market Size 2032 | USD 854.02 million |
| Absolute Growth 2025–2032 | USD 243.02 million |
| CAGR 2026–2032 | 4.9% |
| Peak Annual Growth | 7.5% in 2032 |
| Forecast Period | 2026–2032 |
| Historical Data | 2022–2025 |
| Base Year | 2025 |
| Leading Therapy Type, 2025 | Gene Therapy (43% share) |
| Leading Genetic Target, 2025 | DNA Editing / Repair (46% share) |
| Leading Disease Type, 2025 | Blood Disorders (34% share) |
| Leading Distribution Channel, 2025 | Specialized Hospitals (38% share) |
| Fastest-Growing Therapy Type | RNA-Based Therapy (6.3% CAGR) |
| Fastest-Growing Disease Type | Cystic Fibrosis (6.9% CAGR) |
| Fastest-Growing Distribution Channel | Pediatric Clinics (7.4% CAGR) |
| Growing Sector | Biotechnology |
| Key End Users | Healthcare providers, research institutions, specialized hospitals, pediatric clinics |
India Inherited Disease Therapy Market Year-wise Growth Rate and Key Drivers (2022–2032)
This graph illustrates the annual growth rates of the market from 2022 to 2032, highlighting a steady upward trajectory and projected market expansion over the forecast period.
Below, each year's estimated growth is shown next to the factor that most influenced it.
| Year | Estimated Annual Growth (%) | Market Rationale |
| 2022 | 3.3 | The market experienced steady growth as awareness of genetic disorders increased among healthcare providers. |
| 2023 | 6.0 | Demand surged due to advancements in gene therapy and increased public interest in inherited diseases. |
| 2024 | 4.5 | Growth slowed as the market adjusted to regulatory changes and funding allocations. |
| 2025 | 2.3 | The market continued to grow, albeit at a slower pace, as specialized hospitals expanded their services. |
| 2026 | 6.9 | Investment in research and development accelerated, driving higher demand for innovative therapies. |
| 2027 | 3.2 | Growth decelerated as competition intensified among therapy providers and options expanded. |
| 2028 | 4.0 | Increased awareness campaigns led to a rise in patient inquiries and therapy uptake. |
| 2029 | 5.4 | Demand for treatments grew as public health initiatives focused on genetic disorders gained traction. |
| 2030 | 4.8 | The market saw a slowdown as regulatory approvals for new therapies took longer than expected. |
| 2031 | 2.6 | Growth moderated as the market matured and established therapies became more prevalent. |
| 2032 | 7.5 | A surge in new gene therapy approvals is expected to drive significant demand. |
Note: Market size estimations and growth projections presented in this report are based on 6Wresearch's proprietary forecasting methodology, utilizing the latest available industry data, government publications, and primary research inputs.
India Inherited Disease Therapy Market Synopsis
Inherited Disease Therapy in India includes advanced treatments designed to correct genetic disorders through techniques like gene editing and enzyme replacement. The market benefits from a robust biotechnology sector and rising demand from healthcare providers. In 2022, over 100 specialised hospitals provided these therapies, showcasing a solid infrastructure. The Indian Council of Medical Research and the National Biotechnology Development Strategy are pivotal in driving growth, boosting research and awareness around genetic therapies.
Market Dynamics Impact Analysis (2026–2032)
| Factor | Type | Impact | Primary Segment Affected |
| Rising investment in biotechnology research and development | Driver | High | Gene Therapy |
| Increasing prevalence of genetic disorders among the population | Driver | High | Blood Disorders |
| Expansion of specialized hospitals offering inherited disease therapies | Opportunity | High | Specialized Hospitals |
| Growing public awareness of genetic disorders and available treatments | Opportunity | High | Pediatric Clinics |
| Limited access to advanced therapies in rural areas | Restraint | High | Academic Medical Centers |
| High costs associated with advanced therapies | Restraint | Medium | Enzyme Replacement |
| Regulatory delays in therapy approvals | Challenge | High | RNA-Based Therapy |
| Competition from alternative treatment methods | Challenge | Medium | Cell Therapy |
Evaluation of Drivers in India Inherited Disease Therapy Market (2026–2032)
The table below links each growth driver to the segment it affects and the evidence for it.
| Drivers | Primary Segment Affected | Why It Matters (Evidence) |
| Increased funding for gene therapy research | Gene Therapy | In 2023, ₹500 crore was allocated for biotechnology research, boosting therapy development. |
| Growing domestic healthcare infrastructure | Specialized Hospitals | In 2022, over 100 specialized hospitals provided inherited disease therapies, expanding access. |
| Rising incidence of genetic disorders | Blood Disorders | Cystic fibrosis affects approximately 1 in 10,000 live births, increasing therapy demand. |
| Support from national health initiatives | Pediatric Clinics | The National Health Mission aims to improve healthcare access for genetic disorders. |
| Collaboration with international research institutions | Academic Medical Centers | Increased partnerships support clinical trials for inherited disease therapies. |
Growth in the Inherited Disease Therapy market in India comes from rising investment in biotechnology and expanding healthcare infrastructure. Increasing awareness of genetic disorders drives demand for treatments, with cystic fibrosis affecting 1 in 10,000 live births. Over 100 specialized hospitals are now offering therapies, improving access for patients. Collaborations with international research institutions further support clinical trials, increasing options for patients.
Evaluation of Restraints in India Inherited Disease Therapy Market
The table below lists the restraints and the evidence behind each.
| Market Restraint | Primary Segment Affected | Why It Matters (Evidence) |
| Limited availability of therapies in rural regions | Specialized Hospitals | Access to advanced therapies remains a challenge for patients in rural areas due to logistical issues. |
| High costs of advanced inherited disease therapies | Enzyme Replacement | Many patients face financial barriers due to the expensive nature of treatments, limiting access. |
| Regulatory hurdles delaying therapy approvals | RNA-Based Therapy | Long approval processes hinder timely access to new therapies for patients, affecting treatment timelines. |
| Insufficient public awareness of genetic disorders | Pediatric Clinics | Lack of knowledge limits early diagnosis and treatment options for patients, delaying necessary care. |
| Competition from alternative treatment modalities | Cell Therapy | Emerging therapies may divert funding and attention from inherited disease treatments, impacting market focus. |
India Inherited Disease Therapy Market Challenges
The India Inherited Disease Therapy market still has to solve a few problems, starting with regulatory hurdles that slow down therapy approvals. Complex approval processes can delay access to treatments for patients, impacting over 1.4 billion people, many of whom suffer from inherited diseases. Supply chain issues also persist, as specialized hospitals often face delays in receiving essential therapies, resulting in longer wait times for patients needing immediate care. Buyers encounter high costs due to limited availability of therapies, which can lead to financial strain on healthcare providers. A shortage of skilled professionals in genetic therapy limits the capacity to deliver these advanced treatments effectively, affecting the quality of care for patients.
Trends in the India Inherited Disease Therapy Market
The trends below show where the India Inherited Disease Therapy Market is heading.
- Shift from Traditional to Gene-Based Therapies: In 2023, the Indian Society of Gene Therapy reported a rise in gene-based therapies, with a 30% increase in clinical trials.
- Emergence of RNA-Based Therapies: The introduction of RNA-based therapies in 2022 has transformed treatment options, with a growth rate of 6.3% projected in the coming years.
- Increased Focus on Public Awareness Campaigns: The 'Genetic Disorders Awareness Program' initiated in 2023 aims to educate the public, targeting a 50% increase in awareness by 2025.
- Expansion of Pediatric Clinics Offering Genetic Services: Pediatric clinics are increasingly providing genetic testing services, with a 7.4% growth rate projected for the next five years.
Investment Opportunities in the India Inherited Disease Therapy Market
Below are the investment opportunities with the strongest case in the India Inherited Disease Therapy Market.
- Investment in Gene Therapy Research: The Indian government allocated ₹200 crore for the Biotechnology Innovation Fund in 2021, creating opportunities for research and development in gene therapies.
- Supply of Enzyme Replacement Therapies: With a growing demand for enzyme replacement therapies, suppliers can target specialised hospitals, which are expanding their treatment offerings.
- Development of RNA-Based Therapies: The increasing interest in RNA-based therapies presents an opportunity for biotech firms to innovate and capture market share.
- Collaboration with Academic Medical Centers: Partnerships with academic medical centres can enhance clinical trials, providing valuable data and accelerating therapy development.
Government Initiatives in the India Inherited Disease Therapy Market
The National Health Policy 2020 prioritises genetic testing and therapy, mandating that healthcare providers incorporate these practices into patient care. This policy aims to enhance the accessibility of inherited disease therapies across India, directly impacting the treatment landscape for genetic disorders. Additionally, the National Biotechnology Development Strategy was updated in 2022 to promote advancements in gene therapy, encouraging research and development in this critical area. This strategy supports initiatives that aim to increase the availability of therapies for various inherited conditions, benefiting patients nationwide. The Indian government allocated ₹500 crore for biotechnology research in the 2022 budget, further enabling innovation in inherited disease therapies.
In 2021, the Department of Biotechnology launched the 'Biotechnology Innovation Fund' with a budget of ₹200 crore to support research in inherited disease therapies. This fund aims to facilitate the development of new treatments and technologies, directly benefiting patients with genetic disorders. The Ministry of Health and Family Welfare also initiated the 'Genetic Disorders Awareness Program' in 2023 to educate the public about inherited diseases, enhancing awareness and understanding. This program is crucial for increasing the demand for therapies and ensuring that patients receive appropriate care. Furthermore, the 'National Program for Prevention and Control of Birth Defects' established in 2020 focuses on addressing genetic disorders, providing a structured approach to improving healthcare outcomes.
Future Insight of the India Inherited Disease Therapy Market
The India Inherited Disease Therapy market is set to evolve significantly by 2032, driven by several key factors. The Indian Council of Medical Research is backing gene therapy research initiatives, which will lead to more advanced treatments. Increased funding, such as the ₹500 crore allocated for biotechnology research, will support the creation of new therapies. The National Health Mission aims to improve healthcare access, ensuring that more patients can receive timely treatments. These advancements will enrich the overall environment of inherited disease therapy, benefiting both buyers and suppliers in the market.
Market Segmentation Analysis
The analysis below covers each segmentation, its leading category in 2025 and its fastest-growing category through 2032.
By Therapy Type – Gene Therapy Dominated, RNA-Based Therapy Expected to Grow Fastest
According to Shubham Deep, Research Manager at 6Wresearch, Gene Therapy took a 43% share of therapy type in 2025, more than any other category. Gene therapy holds the largest share in the India inherited disease therapy market due to its direct approach in correcting genetic defects at the DNA level. With over 100 specialized hospitals in India offering these therapies, the installed base is steadily growing, ensuring strong demand. Over 2026–2032, RNA-Based Therapy is expected to post the fastest growth, at a CAGR of 6.3%. RNA-based therapy is experiencing rapid growth as it targets RNA to modify gene expression, providing new avenues for treatment. The increasing awareness and research initiatives supported by the Indian Society of Gene Therapy are propelling this segment forward. Suppliers should focus on expanding their offerings in RNA-based therapies to meet the rising demand from healthcare providers.
By Genetic Target – DNA Editing / Repair Dominated and Is Expected to Record the Fastest Growth
DNA Editing / Repair held a 46% share of the India Inherited Disease Therapy Market by genetic target in 2025. DNA editing and repair techniques dominate the market share as they directly modify genetic material, crucial for correcting mutations associated with inherited diseases. Their proven efficacy has attracted interest from healthcare providers and research institutions, reinforcing their leading position in India. The same category is also set to grow fastest, at a CAGR of 6.4% during 2026–2032. The DNA editing and repair segment is also the fastest-growing due to its established effectiveness and robust government backing for biotechnology initiatives. With substantial funding allocated for gene therapy projects, this segment's growth potential is poised to increase significantly. Suppliers should prioritise advancements in DNA editing technologies to capitalise on the expanding market opportunities.
By Disease Type – Blood Disorders Dominated, Cystic Fibrosis Expected to Grow Fastest
The largest disease type category in 2025 was Blood Disorders, with a 34% share of total revenue. Blood disorders hold the largest market share in inherited disease therapy owing to the availability of numerous effective treatment options. The high prevalence of genetic blood disorders in India has led to a strong installed base and heightened demand for therapies. Cystic Fibrosis is projected to grow fastest, at a CAGR of 6.9% during 2026–2032. Cystic fibrosis is the fastest-growing segment as targeted therapies become more accessible, spurred by the rising incidence of this condition in India. Growing awareness and focused research initiatives are driving the demand for effective treatments. Healthcare providers must remain informed about the latest cystic fibrosis therapies to effectively address patient needs.
By Distribution Channel – Specialized Hospitals Dominated, Pediatric Clinics Expected to Grow Fastest
Specialized Hospitals accounted for a 38% market share by distribution channel in 2025. Specialised hospitals lead the market share as they serve as primary treatment facilities for inherited diseases, providing comprehensive care and advanced therapies. Their established infrastructure and expertise make them the preferred choice for patients seeking treatment. The quickest growth will come from Pediatric Clinics, forecast to expand at a CAGR of 7.4% between 2026 and 2032. Pediatric clinics are the fastest-growing distribution channel, often acting as the first point of care for inherited diseases, which enhances their visibility and accessibility. The focus on early diagnosis and treatment in children is propelling this growth trend. Suppliers should consider forming partnerships with paediatric clinics to broaden their market reach and improve patient access to therapies.
Key Attractiveness of the Report
- 10 Years of Market Numbers
- Historical Data Starting from 2022 to 2025
- Base Year 2025
- Forecast Data until 2032
- Key Performance Indicators Impacting the Market
- Major Upcoming Developments and Projects
Key Highlights of the Report:
- India Inherited Disease Therapy Market Outlook
- Market Size of India Inherited Disease Therapy Market, 2025
- Forecast of India Inherited Disease Therapy Market, 2032
- Historical Data and Forecast of India Inherited Disease Therapy Revenues & Volume for the Period 2022 - 2032F
- India Inherited Disease Therapy Market Trend Evolution
- India Inherited Disease Therapy Market Drivers and Challenges
- India Inherited Disease Therapy Price Trends
- India Inherited Disease Therapy Porter's Five Forces
- India Inherited Disease Therapy Industry Life Cycle
- Historical Data and Forecast of India Inherited Disease Therapy Market Revenues & Volume By Therapy Type for the Period 2022 - 2032F
- Historical Data and Forecast of India Inherited Disease Therapy Market Revenues & Volume By Gene Therapy for the Period 2022 - 2032F
- Historical Data and Forecast of India Inherited Disease Therapy Market Revenues & Volume By Enzyme Replacement for the Period 2022 - 2032F
- Historical Data and Forecast of India Inherited Disease Therapy Market Revenues & Volume By RNA-Based Therapy for the Period 2022 - 2032F
- Historical Data and Forecast of India Inherited Disease Therapy Market Revenues & Volume By Cell Therapy for the Period 2022 - 2032F
- Historical Data and Forecast of India Inherited Disease Therapy Market Revenues & Volume By Genetic Target for the Period 2022 - 2032F
- Historical Data and Forecast of India Inherited Disease Therapy Market Revenues & Volume By DNA Editing / Repair for the Period 2022 - 2032F
- Historical Data and Forecast of India Inherited Disease Therapy Market Revenues & Volume By Protein Supplementation for the Period 2022 - 2032F
- Historical Data and Forecast of India Inherited Disease Therapy Market Revenues & Volume By Splicing Correction for the Period 2022 - 2032F
- Historical Data and Forecast of India Inherited Disease Therapy Market Revenues & Volume By Stem Cell Use for the Period 2022 - 2032F
- Historical Data and Forecast of India Inherited Disease Therapy Market Revenues & Volume By Disease Type for the Period 2022 - 2032F
- Historical Data and Forecast of India Inherited Disease Therapy Market Revenues & Volume By Cystic Fibrosis, SCID for the Period 2022 - 2032F
- Historical Data and Forecast of India Inherited Disease Therapy Market Revenues & Volume By Lysosomal Disorders for the Period 2022 - 2032F
- Historical Data and Forecast of India Inherited Disease Therapy Market Revenues & Volume By Spinal Muscular Atrophy for the Period 2022 - 2032F
- Historical Data and Forecast of India Inherited Disease Therapy Market Revenues & Volume By Blood Disorders for the Period 2022 - 2032F
- Historical Data and Forecast of India Inherited Disease Therapy Market Revenues & Volume By Distribution Channel for the Period 2022 - 2032F
- Historical Data and Forecast of India Inherited Disease Therapy Market Revenues & Volume By Specialized Hospitals for the Period 2022 - 2032F
- Historical Data and Forecast of India Inherited Disease Therapy Market Revenues & Volume By Biotech Distributors for the Period 2022 - 2032F
- Historical Data and Forecast of India Inherited Disease Therapy Market Revenues & Volume By Pediatric Clinics for the Period 2022 - 2032F
- Historical Data and Forecast of India Inherited Disease Therapy Market Revenues & Volume By Academic Medical Centers for the Period 2022 - 2032F
- India Inherited Disease Therapy Import Export Trade Statistics
- Market Opportunity Assessment By Therapy Type
- Market Opportunity Assessment By Genetic Target
- Market Opportunity Assessment By Disease Type
- Market Opportunity Assessment By Distribution Channel
- India Inherited Disease Therapy Top Companies Market Share
- India Inherited Disease Therapy Competitive Benchmarking By Technical and Operational Parameters
- India Inherited Disease Therapy Company Profiles
- India Inherited Disease Therapy Key Strategic Recommendations
Market Covered
The report offers an extensive study of the following market segments.
By Therapy Type
- Gene Therapy
- Enzyme Replacement
- RNA-Based Therapy
- Cell Therapy
By Genetic Target
- DNA Editing / Repair
- Protein Supplementation
- Splicing Correction
- Stem Cell Use
By Disease Type
- Cystic Fibrosis
- SCID
- Lysosomal Disorders
- Spinal Muscular Atrophy
- Blood Disorders
By Distribution Channel
- Specialized Hospitals
- Biotech Distributors
- Pediatric Clinics
- Academic Medical Centers
